Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Americas' neglected diseases "need multisector approach":

This article was originally published in Clinica

Executive Summary

The Pan American Health and Education Foundation (PAHEF) is calling for more "multisector partnerships" in support of efforts to tackle neglected diseases in the Americas. The issue was the central theme of a conference co-hosted by PAHEF and Harvard University's Ash Institute for Democratic Governance and Innovation (Cambridge, Massachusetts, March 31-April 3). "Progress is being made" thanks to partnerships with the private sector, but far more needs to be done, especially in the poorest countries, said PAHEF executive director Edward Kadunc at the bi-annual "Frontiers of Innovation" event. Cambridge, Massachusetts-based PAHEF cites projects in Belize, Brazil and Mexico as examples of particular successes to date. Former President of Mexico Vicente Fox was among the attendees.

You may also be interested in...



Swisse Supplements Take Bigger Slice Of Chinese Market

Australian-heritage Swisse grew its share of China's supplements market in 2023 by delivering tailored products to an increasingly health conscious population.

Novartis Draws Out Its APPLAUSE

Another data drop from Fabhalta’s IgAN trial looks encouraging, despite a missing abstract.

More Heartmate Troubles For Abbott. Latest Recall Includes 14 Deaths

Abbott initiated a recall in February of thousands of Heartmate devices due to a system obstruction that can result in serious health outcomes, including death. The FDA has now designated the recall as class I.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT046649

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel